Abstract
This paper provides an overview of orphan drug legislation in the United States. Since passage of the Orphan Drug Act in 1983, 182 designated orphan products have received Food and Drug Administration approval for rare disease treatment or diagnosis. Incentives provided in the act—seven years of marketing exclusivity, protocol assistance, tax credits, the orphan products grant program which authorizes grant moneys to support pivotal clinical trials, and user fee waiver—are discussed. Issues, challenges, and successes are outlined. Important international initiatives in orphan drug legislation triggered by the United States Orphan Drug Act are highlighted.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
